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Free Fatty Acids Link Metabolism and Regulation of the
Insulin-Sensitizing Fibroblast Growth Factor-21
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Sabine Meinus,1 Franziska Reinecke,1 Matthias Mo¨hlig,1 Martin O. Weickert,2 Markus Clemenz,3
Andreas F.H. Pfeiffer,1,2 Ulrich Kintscher,3 Simone Spuler,4 and Joachim Spranger1,2
OBJECTIVE—Fibroblast growth factor (FGF)-21 improves in-
sulin sensitivity and lipid metabolism in obese or diabetic animal
models, while human studies revealed increased FGF-21 levels in
obesity and type 2 diabetes. Given that FGF-21 has been sug-
gested to be a peroxisome proliferator–activator receptor
(PPAR) –dependent regulator of fasting metabolism, we hy-
pothesized that free fatty acids (FFAs), natural agonists of
PPAR, might modify FGF-21 levels.
RESEARCH DESIGN AND METHODS—The effect of fatty
acids on FGF-21 was investigated in vitro in HepG2 cells. Within
a randomized controlled trial, the effects of elevated FFAs were
studied in 21 healthy subjects (13 women and 8 men). Within a
clinical trial including 17 individuals, the effect of insulin was
analyzed using an hyperinsulinemic-euglycemic clamp and the
effect of PPAR activation was studied subsequently in a rosigli-
tazone treatment trial over 8 weeks.
RESULTS—Oleate and linoleate increased FGF-21 expression
and secretion in a PPAR-dependent fashion, as demonstrated
by small-interfering RNA–induced PPAR knockdown, while
palmitate had no effect. In vivo, lipid infusion induced an
increase of circulating FGF-21 in humans, and a strong correla-
tion between the change in FGF-21 levels and the change in FFAs
was observed. An artificial hyperinsulinemia, which was induced
to delineate the potential interaction between elevated FFAs and
hyperinsulinemia, revealed that hyperinsulinemia also increased
FGF-21 levels in vivo, while rosiglitazone treatment had no effect.
CONCLUSIONS—The results presented here offer a mechanism
explaining the induction of the metabolic regulator FGF-21 in the
fasting situation but also in type 2 diabetes and obesity.
Diabetes 58:1532–1538, 2009
Fibroblast growth factor (FGF)-21 is a recentlydiscovered metabolic regulator of fasting metab-olism. FGF-21 activates glucose uptake in adipo-cytes, protects animals from diet-induced obesity
when overexpressed in transgenic mice, and lowers blood
glucose and triglyceride levels when administered to dia-
betic rodents (1–3). Comparably, glucose- and triglyceride-
lowering effects were found in diabetic rhesus monkeys
during chronic FGF-21 treatment over a period of 6 weeks
(4). Therefore, FGF-21 was assumed to be a novel target
with potential antidiabetic properties, which might be
useful in the treatment of hyperglycemia, insulin resis-
tance, and hyperlipidemia.
However, human data did not directly support these
assumptions, since increased serum FGF-21 levels were
found in obese individuals, patients with type 2 diabetes,
and subjects with metabolic syndrome (5,6). In addition
FGF-21 levels correlated positively not only with adiposity
but also with fasting insulin and triacylglycerols (5). A
recent study (3) reported a significant increase of FGF-21
levels during prolonged fasting. This process appeared to
be peroxisome proliferator–activator receptor (PPAR)
–dependent (2,3), although exact mechanisms leading to
fasting-induced FGF-21 elevations are yet unknown.
Various data support that metabolic parameters them-
selves can modulate the circulating levels of hormones
and adipokines (7–10). Thus, free fatty acids (FFAs)
activate PPARs and were found to be elevated in fasting
conditions. We therefore speculated that FFAs themselves
might regulate FGF-21. This hypothesis is supported by
recent data demonstrating that FGF-21 levels are posi-
tively associated with FFAs (11) and triacylglycerols (3) in
a cross-sectional study population of nondiabetic individ-
uals. Although the direction of that relation is unclear in a
cross-sectional study, it offers a potential mechanism
linking starvation to the increased levels of FGF-21. We
therefore investigated the effect of fatty acids on FGF-21
secretion in HepG2 cells in vitro. Based on these in vitro
data, we performed a randomized controlled trial to ex-
plore whether an increase in circulating FFAs and triacyl-
glycerols modifies FGF-21 levels in humans. Since an
increase of FFAs is known to induce insulin resistance and
hyperinsulinemia, the effect of insulin on FGF-21 was
additionally investigated by performing a hyperinsuline-
mic-euglycemic clamp at baseline of a noncontrolled,
rosiglitazone intervention trial. As some recent animal
data (12) also suggested a PPAR-dependent regulation of
FGF-21, we finally evaluated the effect of the PPAR
agonist, rosiglitazone, in that human trial.
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RESEARCH DESIGN AND METHODS
A total of 13 women and 8 men participated in the first study (lipid study).
Briefly, the individuals were normal weight (BMI 23.7  0.8 kg/m2), were aged
26.4  0.8 years, had a waist-to-hip ratio (WHR) of 0.83  0.02, and had basal
lipid parameters in the normal range (total cholesterol 4.53  0.17 mmol/l,
HDL cholesterol 1.44  0.03 mol/l, LDL cholesterol 2.64  0.14 mmol/l,
triacylglycerols 1.01 0.08 mmol/l, and FFAs 0.68 0.12 mmol/l). None of the
participants had taken any medication for at least 3 months before the study.
All participants were initially screened for any systemic disease or biochem-
ical evidence of impaired hepatic or renal function. Subjects with a history of
hypertension, type 2 diabetes, renal or liver disease, dyslipidemia, heart
failure, or a family history of diabetes or any other endocrine disorder were
excluded from this study. Body weight of the participants was stable for at
least 2 months before the study. The 13 healthy young women had regular
menstrual cycles. Informed written consent was obtained from each
participant.
For the second human trial (PPAR study) 7 male and 10 female volunteers
with impaired glucose tolerance were investigated in a prospective trial. The
individuals were overweight (BMI 32.8  2.2 kg/m2), were aged 59.1  1.6
years, and had a WHR of 0.88  0.03. Body weights were stable for at least 2
months before the study. All participants were initially screened for any
systemic disease or biochemical evidence of impaired hepatic or renal
function. Treatment with insulin, orally taken antidiabetes medications, or
glucocorticoids was not allowed. Patients with heart failure, impaired hepatic
or renal function, anemia, disturbed coagulation, or any other endocrine
disorder were excluded. Informed written consent was obtained from all
subjects after explanation of the nature, purpose, and potential risks of the
studies. The patients were instructed not to modify their way of living (diet
and exercise) during the treatment period. All study protocols were approved
by the institutional review board of the Charite´ Medical School, Campus
Benjamin Franklin.
Cell culture. HepG2 cells were grown in Eagle’s minimum essential medium
with 10% FCS and 1% NEA; 24 h before analysis, HepG2 cells were incubated
with basal serum-free media. To analyze the effect of FFAs, palmitic, oleic, or
linoleic acid (Sigma-Aldrich, Seelze, Germany) or a mixture of these fatty
acids (one-third of each) were dissolved in water with 125 mol/l NaOH and
10 mol/l fatty acid–free bovine serum albumin (BSA) (Calbiochem, Ger-
many) in a concentration of 160 mol/l (Ratio 16:1) and cells were incubated
within that medium for 1, 2, 4, 8, and 24 h. Time course and concentration-
dependent effects of FFAs on FGF-21 secretion and expression were analyzed.
Finally, FGF-21 mRNA expression was also studied in primary human
myoblasts. Therefore, primary human myoblasts were prepared from human
skeletal muscle of healthy individuals und cultured in skeletal muscle cell
growth medium (PromoCell, Heidelberg, Germany) containing 10% fetal
bovine serum and 1.5% glutamine and gentamicin. After the first passage,
myoblasts were separated from fibroblasts by neural cell adhesion molecule–
labeled magnetic beads (Miltenyi Biotech, Bergisch-Gladbach, Germany).
To analyze the effect of lecithin and glycerol on FGF-21 secretion, HepG2
cells were incubated for 4 h using a concentration of 2.5 mg/ml lecithin (Fluka;
Sigma-Aldrich) and 1 mmol/l glycerol (Sigma-Aldrich). The FGF-21 levels were
measured in the supernatant and normalized to total protein levels.
Small-interfering RNA (siRNA) experiments were performed to investigate
whether those effects depend on PPAR. Therefore, siRNA for PPAR (nos.
D-003434-01 and D-003434-02) and nontargeting siRNA (no. D-001210-01) as
control was purchased from Dharmacon (Thermo Scientific). A total of 100
pmol/well of each siRNA and electroporation with Amaxa nucleofector II
(Lonza Cologne, Cologne, Germany) was used for transfection. FFA stimula-
tions were performed 48 h after transfection. All in vitro experiments were
performed using at least five replicates per treatment.
The FGF-21 levels were measured in the supernatant by radioimmunoassay
(Phoenix Europe, Karlsruhe, Germany) using 125 I–labeled FGF-21 as a tracer
and normalized on total protein levels. Protein quantification was performed
using the Roti-Nanoquant (Karl-Roth, Karlsruhe, Germany). For RT-PCR 20 ng
of total RNA per well were used and FGF-21 RNA was analyzed according to
the manufacturer’s the instructions of the iScript SYBR green RT-PCR Kit
(Biorad, Hercules, CA). Real-time quantitative PCR was performed using an
ABI PRISM 7300 Real-Time PCR System (Applied Biosystems, Foster City,
CA). Primer sequences will be sent upon request. The ddCt-method (change in
dCt [ Ct of the target gene minus Ct of the housekeeping gene]) was used for
relative quantification. Fold changes in expression were calculated according
to the transformation: fold increase  2 difference in dCt.
Human trials
Lipid study. Eligible participants were randomly assigned to receive either
lipid/heparin infusion (LHI) or saline/heparin infusion (SHI) in a cross-over
design for the lipid study. A randomization list was created using block
randomization (13). In women, the study was performed during the early
follicular phase of two subsequent menstrual cycles (days 4–6). To avoid
interactions between the study procedures, the study was performed at
intervals of at least 2 days in men. Following a 10-h overnight fast, a short
polyethylene catheter was inserted into an antecubital vein for infusion of test
substances at 0800 h. Another catheter was placed into the contralateral
forearm vein for blood sampling. A 0.9% saline infusion plus heparin (0.4 units 
kg1  min1) or a lipid infusion (Abbolipid 20% [contents in 1.000 ml: 100 g
soybean oil, 100 g safflower oil, 25.0 g glycerol, and 12.0 g egg phospholipids],
Abbott, Wiesbaden, Germany; or Lipoveno¨s 20% [contents in 1.000 ml: 200 g
soybean oil, 25.0 g glycerol, 12.0 g egg phospholipids, and 0.3 goleate],
Fresenius Kabi, Bad Homburg, Germany) plus heparin (0.4 units  kg1 
min1) was infused at a constant rate of 1.5 ml/min for 330 min. Four hours
after the start of the saline/heparin infusion a hyperinsulinemic-euglycemic
clamp (14) was started in six subjects. This procedure was described
previously (15).
PPAR study. Each subject was studied before and after an 8-week
rosiglitazone treatment (2  8 mg/day; GlaxoSmithKline, Mu¨nchen, Germany)
using an oral glucose tolerance test and a hyperinsulinemic-euglycemic clamp
as described previously (16). In brief, 40 mIU/m2 per min human insulin
(Actrapid; Novo Nordisk, Bagsvaard, Denmark) and a variable infusion of 10%
glucose (Serag Wiessner, Naila, Germany) was used, and capillary glucose
concentration was monitored every 5 min and was maintained between 4.0
and 4.9 mmol/l via variation of the glucose infusion rate. Insulin sensitivity
was assessed as M value and was calculated by dividing the average glucose
infusion rate (mg glucose/min) during the steady state of the clamp by the
body weight.
Laboratory tests. Plasma FGF-21 levels were measured before and during
LHI SHI, and steady state at the end of the hyperinsulinemic-euglycemic
clamp. Metabolic parameters, including FFAs, triacylglycerols, total choles-
terol, LDL cholesterol, HDL cholesterol, glucose, and insulin were determined
as described previously (7). Serum FGF-21 levels were determined by
radioimmunoassay (Phoenix Europe) using 125 I–labeled FGF-21 as tracer.
The linear range of the assay was 0.5–8.5 ng/ml, and the standard range was
0.234–30 ng/ml. The interassay and intra-assay coefficients of variation were
5.0 and 14%, respectively.
Statistical analysis. All statistical procedures were performed using SPSS
version 15.0 (SPSS, Chicago, IL). Profiles of FFAs, insulin, glucose, triacylg-
lycerols, and FGF-21 were compared by repeated-measures ANOVA with
treatment and time as within-subject factors and the Huynh-Feldt- procedure
as correction factor, which corrects for a positive biased F test for within-
subject factors. The area under the concentration time curve (AUC) was
calculated by using the trapezoidal integration. The change in FGF-21, FFAs,
glucose, triacylglycerols and insulin between baseline and after LHI and SHI
was calculated by subtracting the baseline value from the value 4 h after each
infusion procedure. Data were compared by paired Student’s t test for
normally distributed data and Wilcoxon test for skewed data. The correlations
between the values were estimated by Pearson’s correlation test and adjusted
for age, sex BMI, and change in insulin. The unpaired t test or Mann-Whitney
test was used for group comparison, as appropriate. A general linear model
analysis was used to control for potential confounders. Results were consid-
ered to be significant if the two-sided  was 0.05. Data are presented as
means  SE, unless otherwise indicated.
RESULTS
Fatty acids stimulate release of FGF-21 in HepG2
cells in a PPAR-dependent fashion. Incubation of
HepG2 cells with a mixture of palmitic, linoleic, or oleic
acid induced an increase in FGF expression and secretion
compared with the BSA control. The analysis of the
individual fatty acids revealed that this increase was not
detectable for palmitic acid, while stimulation with oleic
or linoleic acid resulted in a significant elevation of FGF-21
secretion. Within those experiments, linoleic acid had the
strongest effect at 	4–8 h (Fig. 1A–D), and we analyzed
time course–dependent changes in mRNA expression
(Fig. 2). The maximum of those effects was observed at
2–4 h for FGF-21 expression and 4–8 h for protein
secretion, a time course in line with our in vivo experi-
ments. Furthermore, the dose-response experiments using
different oleate-to-BSA ratios (control vs. 1:1, 2:1, 4:1, 8:1,
and 16:1) suggested an increase in FGF-21 secretion in a
dose-dependent manner (6.61  0.81 vs. 6.93  1.25,
7.36  1.18, 8.98  1.18, 9.66  1.65, and 10.47  1.10
K. MAI AND ASSOCIATES
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ng/ml; P  0.05 for control vs. 4:1, 8:1, and 16:1; P  0.05
for 1:1 vs. 8:1 and 16:1; and P  0.05 for 2:1 vs. 16:1).
To evaluate whether these effects were mediated via
PPAR, we performed siRNA experiments. The PPAR-
specific siRNA induced a knockdown of PPAR of 	60%,
although the expression of the PPAR target gene CPT1A
was reduced by only	35%. Despite the incomplete knock-
down of PPAR, the increase in FGF-21 secretion and
mRNA expression during stimulation with linoleate and
FFA mixture was not further observed. Thus, results at
mRNA and protein levels indicate that the FFA-induced
effects on FGF-21 depend on activation of PPAR (Fig. 3).
As lipid infusion contains a mixture of different fatty
acids, glycerol, and lecithin, we analyzed the effect of
lecithin and glycerol on FGF-21 secretion in HepG2 cells.
Compared with controls, no significant effect of those
substances was detectable in HepG2 cells. To evaluate the
regulation of FGF-21 expression in human muscle, we
aimed to measure FGF-21 expression in primary human
myoblasts. Actually, no FGF-21 expression was detectable
in these experiments, despite accurate positive controls in
HepG2 cells. Those data suggest that the primary human
myoblasts used here do not express FGF-21; therefore, we
did not analyze the effects of FFAs in those cells.
Lipid infusion induces elevated FGF-21 levels in vivo
in humans in a randomized controlled trial. There was
no baseline difference of FFAs before LHI and SHI (P 
NS). As expected, FFA levels increased during LHI,
whereas only a small increase was seen during SHI,
resulting in significantly higher FFA levels during LHI
compared with SHI (AUC LHI vs. SHI: 1,183.5  66.7 vs.
228.8  17.9 nmol  l1  min1, P  0.001; treatment-vs.-
time interaction: P  0.001) (Fig. 4A). Accordingly, triglyc-
eride levels rose during LHI (P  0.05), while a moderate
decrease was observed during SHI (P  0.05), finally also
resulting in significantly higher triglyceride levels during
LHI (AUC LHI vs. SHI: 1,360.6  172.0 vs. 134.0  12.5
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FIG. 1. Protein levels of FGF-21 in the supernatant of HepG2 cells after stimulation with palmitate (A), oleate (B), linoleate (C), and an FFA
mixture (D) for 1, 2, 4, 8, and 24 h. Results are expressed as means  SE. *P < 0.05 vs. BSA at the same time point, P  0.072 for FGF-21 protein
levels during linoleate stimulation at 2 h vs. BSA, P  0.069 for FGF-21 protein levels during linoleate stimulation at 8 h vs. BSA, respectively.
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FIG. 2. mRNA Expression of FGF-21 in HepG2 cells after stimulation
with linoleate for 1, 2, 4, and 8 h. Results are expressed as means SE.
*P < 0.05 vs. BSA at the same time point.
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nmol  l1  min1, P  0.05, P  0.01; treatment-vs.-time
interaction: P  0.001) (Fig. 4B).
Glucose levels were unchanged during both LHI and SHI
(baseline: 4.91  0.80 vs. 4.84  0.54 mmol/l, treatment-
vs.-time interaction: P  NS; AUC LHI vs. SHI: 1,130.0 
24.9 vs. 1,110.1  17.6 mmol  l1  min1; P  NS). No
change of insulin levels was observed during LHI com-
pared with baseline (baseline: 5.17  0.53 vs. 4 h: 4.97 
0.62 mU/l; P  NS), while a small, but progressive, decline
in insulin concentration was detected during SHI (base-
line: 5.80  0.76 vs. 4 h: 2.98  0.32 mU/l; P  0.05). This
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FIG. 3. A: Gene expression of FGF-21, CPT1A, and PPAR in HepG2
cells in BSA medium after siRNA knockdown of PPAR compared with
control siRNA (100%). Results are expressed as means SE. *P< 0.05
vs. expression during control siRNA, respectively. B: FGF-21 mRNA
expression in HepG2 cells during linoleate or FFA mixture stimulation
after siRNA knockdown of PPAR (compared with control siRNA and
BSA stimulation [100%]). Results are expressed as means  SE. *P <
0.05 vs. expression during control siRNA, respectively. C: Concentra-
tion of FGF-21 in the supernatant of HepG2 cells after siRNA knock-
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mixture compared with control siRNA and BSA medium. Results are
expressed as means  SE. *P < 0.05 vs. control siRNA and BSA
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decline resulted in lower insulin values during SHI com-
pared with LHI (AUC LHI vs. SHI: 1,384.2  132.5 vs.
1,021.8  109.8 mU  l1  min1, P  0.001; treatment-vs.-
time interaction: P  0.001).
While no change of FGF-21 levels was detected during
SHI (P  NS), an increase in FGF-21 levels was found
during LHI (P  0.05). Thus, FGF-21 levels were signifi-
cantly higher during LHI compared with SHI (treatment-
vs.-time interaction: P 0.05.; AUC: 1,191 91 vs. 1,090
86 ng  ml1  min1; P  0.05) (Fig. 4C). In six individuals,
an hyperinsulinemic-euglycemic clamp was started at 240
min. Notably, we found at 300 min a progressive and highly
significant increase of FGF-21 in the remaining 15 partic-
ipants, who had an isolated lipid infusion over a total of
300 min (P  0.001; data not shown). Indeed, the circulat-
ing FGF-21 levels were nearly doubled at that time point.
Interestingly, the change of FGF-21 levels compared with
baseline was positively correlated to the change of FFA
levels during both LHI and SHI (r  0.528, P  0.001) (Fig.
5). Given the circadian changes in the control group, we
also included the saline group in the correlation analysis
between changes of FFAs and FGF-21. Most importantly,
no correlation was found between the change of FGF-21
levels and the change of insulin levels during LHI and SHI,
while the correlation between FFAs and FGF-21 was
robust, even after adjustment for additional confounders
(age, sex BMI, and 
insulin) (r  0.474, P  0.005).
As in some participants, the lipid infusion induced a
reduction in FGF-21 concentrations, and we separated
those participants according to the change in FGF-21
levels during LHI. However, no significant difference was
found between both groups concerning their sex, age BMI
WHR, baseline levels of blood glucose, fasting FGF-21,
fasting FFAs, and homeostasis model assessment values.
To delineate a potential interaction of lipid- and insulin-
induced effects on FGF-21, we additionally analyzed hy-
perinsulinemic-euglycemic clamps, which were performed
at baseline in a rosiglitazone treatment trial in 17 subjects
with impaired glucose tolerance. Steady-state blood sam-
ples were taken not less than 3 h after start of insulin
infusion. An 	700% increase of insulin levels was ob-
served during this protocol (P  0.005). Under those
conditions, a small but significant increase in FGF-21
levels during hyperinsulinemia was observed in these
subjects (Fig. 6).
PPAR stimulation and FGF-21. As expected and de-
scribed in numerous studies, the glucose response dur-
ing the oral glucose tolerance test and insulin sensitivity
were improved after 8 weeks of rosiglitazone treatment.
However, no change in serum FGF-21 levels was ob-
served (Fig. 7).
The accuracy of the FGF-21 assay was investigated by
adding various amounts of lipid solution (Lipoveno¨s 20%;
Fresenius Kabi, Bad Homburg, Germany) (0, 0.5, 1.5, and
2.5% vol/vol) to human plasma samples. This ex vivo
addition of lipid infusion resulted in measured triglyceride
concentrations of 1.28, 3.56, 8.09, and 12.69 mmol/l.
FGF-21 values did not differ significantly between those
samples. We next added 6 mmol/l oleic acid or linoleic
acid to these 0, 0.5, 1.5, and 2.5% vol/vol triglyceride
dilutions, resulting in FFA concentrations comparable
with those in plasma samples during lipid infusion (4.57–
7.31 mmol/l). The subsequently measured FGF-21 values
were not significantly different, neither for oleic acid nor
for linoleic acid. Taken together, neither triglyceride nor
FFA concentrations similar to those observed in vivo in
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FIG. 7. Effect of PPAR stimulation by rosiglitazone treatment on
FGF-21 levels in subjects with impaired glucose tolerance. Results are
expressed as means  SE.
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the present study interfered with the measured concentra-
tions of FGF-21.
DISCUSSION
Various recent cross-sectional studies (5,6,11) described a
positive correlation between FGF-21 levels and parame-
ters of lipid metabolism, specifically FFAs and triacylglyc-
erols. However, existing experimental data regarding
FGF-21 did not yet elucidate the direction of that relation-
ship. Both, the experimental data presented here and the
results of the controlled, randomized cross-over human
trial strongly suggest a direct regulation of circulating
FGF-21 levels in humans by FFAs. Interestingly, insulin
appears to have an independent effect on circulating
FGF-21, although our data, respective of that effect, are
not based on a controlled trial and future studies are
required to further strengthen that finding.
In terms of physiology, the FFA-induced increase of
FGF-21 might contribute to the adaption of the organism
to starvation. In response to fasting, FGF-21 is known to
be stimulated by activation of the PPAR, a nuclear
receptor, which is itself activated by fatty acids (2,17).
FFAs usually increase during fasting, suggesting that a
stimulation of FGF-21 secretion may be induced by in-
creased FFAs directly via PPAR activation, an assump-
tion that is strongly underlined by our data. The relevance
of PPAR in the regulation of FGF-21 was supported by
recent data (3) showing increased FGF-21 levels after
pharmacological PPAR activation using fibrates. FGF-21
increased insulin sensitivity in animal experiments and
attenuated the hormone-stimulated lipolysis in human
adipocytes probably due to reduced expression of perili-
pin, a phosphoprotein that is thought to recruit several
lipases to the surface of the lipid droplets for subsequent
triglyceride hydrolysis (18). These biological properties
suggest that FGF-21 may contribute to the anabolic switch
of the organism under conditions of starvation and the
mechanism presented here might explain the previously
described elevated FGF-21 levels in patients with preva-
lent lipid disorders, obesity, or diabetes.
The insulin-sensitizing effect of FGF-21 has been con-
vincingly demonstrated within animal experiments. As
current data suggest differential effects of saturated and
unsaturated fatty acids, and especially polyunsaturated
fatty acids on glucose metabolism (19), it is tempting to
speculate that some of these effects might be mediated by
FGF-21. Indeed unsaturated fatty acids, and specifically
the polyunsaturated linoleic acid, stimulated FGF-21 se-
cretion, while the saturated fatty acid palmitic had no
effect on FGF-21 secretion in HepG2 cells. Various studies
suggested that the FFA-induced activation of PPAR de-
pends on the degree of saturation of those FFAs (20).
Therefore, the different effects on FGF-21 secretion may
be caused by different PPAR binding of saturated and
unsaturated fatty acids. Whether such mechanism contrib-
utes to the fatty acid–specific effects regarding the devel-
opment of metabolic disorders remains to be elucidated.
A negative correlation between fasting insulin and
FGF-21 levels was recently described in diabetic subjects
(6,11), while this association was reported to be positive in
obese individuals (5). Given this discrepancy, the relation-
ship between insulin and FGF-21 is unclear. Since we
observed slightly higher insulin levels during LHI com-
pared with SHI in our participants, hyperinsulinemic-
euglycemic clamps were performed for an in-depth
analysis of the effects of insulin on FGF-21 levels. The
slight increase of FGF-21 by hyperinsulinemia supports an
independent effect of insulin on the regulation of FGF-21.
Given a well-known reduction of FFAs during hyperinsu-
linemia, this effect may have been even underestimated.
These results are in line with recent data of Izumiya et al.
(21), showing that activation of AKT contributes to the
expression of FGF-21. Thus, hyperinsulinemia and ele-
vated levels of FFAs might contribute together to the
elevated FGF-21 levels seen in diabetic patients (5,6).
Nevertheless, both in vivo and in vitro data support a
direct effect of FFAs on FGF-21 expression and secretion,
suggesting that the effect of FFAs seen in our lipid trial
would be at least in part independent of the moderate
hyperinsulinemia, which occurs in the time frame pre-
sented here compared with the control group. Most im-
portantly, no correlation was found between the change of
FGF-21 levels and the change of insulin levels during LHI
and SHI, a fact that is in line with an independent effect of
FFAs on FGF-21 levels.
The FFA-induced effect in liver cells seems to depend on
PPAR stimulation, which is strongly supported by the in
vitro data presented here. However, it should be men-
tioned in that context, other tissues like adipose tissue or
muscle might also contribute to the FFA-induced increase
in FGF-21 in vivo. We do not feel that the fact of absent
FGF-21 expression in primary human myoblasts contra-
dicts a substantial release of FGF-21 from muscle cells in
vivo. Our cells were predominantly undifferentiated cells,
and the degree of differentiation might contribute to the
expression pattern respective of FGF-21. A potential role
of muscle cells was clearly supported by the study of
Izumiya et al. (17), although the relevance of muscle cell
differentiation might require furthers studies.
Even if recent animal data suggested a regulation of
FGF-21 also by PPAR (12), no change of FGF-21 levels
was detected during insulin-sensitizing treatment with
PPAR stimulation in the human trial in subjects with
impaired glucose tolerance (Fig. 5). Although PPAR
agonists may recruit different nuclear cofactors, which
may explain different biological effects, our data do not
support (but also not entirely exclude) that the observed
effects on FGF-21 levels during LHI were mediated in part
by PPAR stimulation.
Limitations of the present study need to be men-
tioned. In a recent study (3), a prolonged fasting situa-
tion was required to increase FGF-21 levels in humans.
Although small effects may have been underestimated in
the abovementioned study, it is noteworthy that the
increase of FFAs during fasting is substantially lower in
comparison to changes observed during lipid infusion.
As such, although the intervention performed here is a
well-established model investigating metabolic effects of
hyperlipidemia (22–26), supraphysiological levels of FFAs,
as observed in the present study, may have reduced the
period potentially required to observe effects of more
moderate FFA elevations on FGF-21. In addition, FFAs
and triacylglycerols are both increased by LHI (27–29),
and the respective effects are difficult to dissociate. Al-
though the correlation between changes in FFAs and
FGF-21 during LHI suggests that FFAs contribute to the
effect on FGF-21, we cannot entirely exclude a role of
triacylglycerols or other compounds within the applied
infusions. Notably, no effect of glycerol or lecithin was
detectable in HepG2 cells, suggesting that those sub-
stances have no substancial effect on FGF-21 secretion.
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Recent human data (6) indicate a specific role of FFAs on
FGF-21 secretion by showing a positive correlation be-
tween both parameters in healthy subjects. Furthermore,
Dostalova et al. (30) observed not only reduced FGF-21
levels but also lower FFAs in anorectic women compared
with control subjects, while no difference in insulin, tria-
cylglycerols, and fasting glucose was detected between
anorectic and healthy women in this study. Those data do
support a model of FFAs as major regulators of FGF-21
levels.
In summary, we demonstrated in vitro that FFAs stim-
ulate FGF-21 expression and secretion in a human hepatic
carcinoma cell line in a PPAR-dependent fashion. The in
vivo relevance of this finding was confirmed in a con-
trolled, randomized cross-over trial in humans. Within that
trial, acutely increased levels of FGF-21 were observed.
Most interestingly, hyperinsulinemia also induced a small
but significant increase of FGF-21, suggesting that both
FFAs and insulin regulate FGF-21, which may explain
elevated levels of FGF-21 in obese and diabetic patients
but offers also a potential mechanism linking regulation of
FGF-21 to the switch of metabolism during starvation.
ACKNOWLEDGMENTS
J.S. was supported by a research group (Molecular Nutrition)
of the Bundesministerium fu¨r Bildung und Forschung, a
graduate school (GK1208), a Heisenberg-Professorship
(SP716/1-1), and a clinical research group of the Deutsche
Forschungsgemeinschaft (KFO192/1). K.B., S.M., M.S., M.M.,
and J.W. were also supported by GK1208. S.S. was also
supported by KFO192/1.
No potential conflicts of interest relevant to this article
were reported.
We thank N. Huckauf and K. Sprengel for excellent
technical assistance.
REFERENCES
1. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R,
Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gro-
mada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F,
Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin
Invest 2005;115:1627–1635
2. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y,
Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC,
Hammer RE, Mangelsdorf DJ, Kliewer SA. Endocrine regulation of the
fasting response by PPARalpha-mediated induction of fibroblast growth
factor 21. Cell Metab 2007;5:415–425
3. Galman C, Lundasen T, Kharitonenkov A, Bina HA, Eriksson M, Hafstrom
I, Dahlin M, Amark P, Angelin B, Rudling M. The circulating metabolic
regulator FGF21 is induced by prolonged fasting and PPARalpha activation
in man. Cell Metab 2008;8:169–174
4. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno
XT, Hansen BC, Shanafelt AB, Etgen GJ. The metabolic state of diabetic
monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007;
148:774–781
5. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL,
Chow WS, Tso AW, Lam KS, Xu A. Serum FGF21 levels are increased in
obesity and are independently associated with the metabolic syndrome in
humans. Diabetes 2008;57:1246–1253
6. Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, Tang Y, Liu H, Boden G.
Circulating FGF-21 levels in normal subjects and in newly diagnose
patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes
2008;116:65–68
7. Mai K, Bobbert T, Reinecke F, Andres J, Maser-Gluth C, Wudy SA, Mohlig
M, Weickert MO, Hartmann MF, Schulte HM, Diederich S, Pfeiffer AF,
Spranger J. Intravenous lipid and heparin infusion-induced elevation in
free fatty acids and triglycerides modifies circulating androgen levels in
women: a randomized, controlled trial. J Clin Endocrinol Metab 2008;93:
3900–3906
8. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M,
Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels
in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968–2974
9. Basu R, Pajvani UB, Rizza RA, Scherer PE. Selective downregulation of the
high molecular weight form of adiponectin in hyperinsulinemia and in type
2 diabetes: differential regulation from nondiabetic subjects. Diabetes
2007;56:2174–2177
10. Blumer RM, van der Crabben SN, Stegenga ME, Tanck MW, Ackermans
MT, Endert E, Van der PT, Sauerwein HP. Hyperglycemia prevents the
suppressive effect of hyperinsulinemia on plasma adiponectin levels in
healthy humans. Am J Physiol Endocrinol Metab 2008;295:E613–E617
11. Li L, Yang G, Ning H, Yang M, Liu H, Chen W. Plasma FGF-21 levels in type
2 diabetic patients with ketosis. Diabetes Res Clin Pract 2008;82:209–213
12. Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, Mu J,
Thompson JR, Berger JP, Wong KK. Adipose fibroblast growth factor 21 is
up-regulated by peroxisome proliferator-activated receptor gamma and
altered metabolic states. Mol Pharmacol 2008;74:403–412
13. Pocock S. In Clinical Trials: A Practical Approach. New York, John Wiley,
1984
14. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for
quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214–
E223
15. Mai K, Bobbert T, Kullmann V, Andres J, Rochlitz H, Osterhoff M, Weickert
MO, Bahr V, Mohlig M, Pfeiffer AF, Diederich S, Spranger J. Free fatty acids
increase androgen precursors in vivo. J Clin Endocrinol Metab 2006;91:
1501–1507
16. Mai K, Andres J, Bobbert T, Maser-Gluth C, Mohlig M, Bahr V, Pfeiffer AF,
Spranger J, Diederich S. Rosiglitazone decreases 11beta-hydroxysteroid
dehydrogenase type 1 in subcutaneous adipose tissue. Clin Endocrinol
(Oxf) 2007;67:419–425
17. Oishi K, Uchida D, Ishida N: Circadian expression of FGF21 is induced by
PPARalpha activation in the mouse liver. FEBS Lett 2008;582:3639–3642
18. Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Ryden M.
FGF21 attenuates lipolysis in human adipocytes: a possible link to
improved insulin sensitivity. FEBS Lett 2008;582:1725–1730
19. Riserus U. Fatty acids and insulin sensitivity. Curr Opin Clin Nutr Metab
Care 2008;11:100–105
20. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and
retinoids control lipid metabolism through activation of peroxisome
proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl
Acad Sci U S A 1993;90:2160–2164
21. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K. FGF21
is an Akt-regulated myokine. FEBS Lett 2008;582:3805–3810
22. Simonsen S, Kjekshus JK. The effect of free fatty acids on myocardial
oxygen consumption during atrial pacing and catecholamine infusion in
man. Circulation 1978;58:484–491
23. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids
on glucose production and utilization in man. J Clin Invest 1983;72:1737–
1747
24. Lewis GF, Vranic M, Harley P, Giacca A. Fatty acids mediate the acute
extrahepatic effects of insulin on hepatic glucose production in humans.
Diabetes 1997;46:1111–1119
25. Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF. Prolonged
elevation of plasma free fatty acids impairs pancreatic -cell function in
obese nondiabetic humans but not in individuals with type 2 diabetes.
Diabetes 2000;49:399–408
26. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona
P. Elevation of free fatty acids induces inflammation and impairs vascular
reactivity in healthy subjects. Diabetes 2003;52:2882–2887
27. Muggeo M, Tiengo A, Fedele D, Crepaldi G. The influence of plasma
triglycerides on human growth hormone response to arginine and insulin:
a study in hyperlipemics and normal subjects. Horm Metab Res 1975;7:
367–374
28. Lindholm M, Eklund JO, Hamberger B, Jarnberg PO. Plasma catechol-
amine and free fatty acid levels during infusion of lipid emulsion in
critically ill patients. Crit Care Med 1984;12:953–956
29. Piatti PM, Monti LD, Baruffaldi L, Magni F, Paroni R, Fermo I, Costa S,
Santambrogio G, Nasser R, Marchi M. Effects of an acute increase in
plasma triglyceride levels on glucose metabolism in man. Metabolism
1995;44:883–889
30. Dostalova I, Kavalkova P, Haluzikova D, Lacinova Z, Mraz M, Papezova H,
Haluzik M. Plasma concentrations of fibroblast growth factors 19 and 21 in
patients with anorexia nervosa. J Clin Endocrinol Metab 2008;93:3627–
3632
FGF-21 AND HYPERLIPIDEMIA
1538 DIABETES, VOL. 58, JULY 2009
